Background Non-alcoholic fatty liver disease (NAFLD) is a common liver disease. The aim of the present study was to explore the relation of visfatin with underlying histopathological changes of NAFLD patients. Subjects A population of 55 NAFLD patients was analyzed in a cross-sectional study. A liver biopsy was realized. Weight, basal glucose, insulin, insulin resistance (HOMA), total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, and visfatin levels were measured. A bioimpedance was performed. Results and conclusions The mean age was 42.8 ± 11.2 years, the mean BMI was 33.1 ± 10.2 with 37 males (67.3%) and 18 females (32.7%). Probabilities to have; portal inflammation increased 1.11 (CI95%:1.03–1.50) with each increment of 1 ng/ml of visfatin concentration, high grade of steatosis increased 1.25 (CI 95%:1.06–1.61) with each unit of insulin concentrations, fibrosis increased 1.12 (CI 95%:1.02–1.43) with each unit of fat mass and lobulillar inflammation increased 13.4 (CI 95%:1.3–147) with each unit of HOMA-IR. Portal inflammation frequencies were different between groups (low visfatin group 13.07 < ng/ml: 37.5% versus high visfatin group 13.07 > ng/ml: 62.5%; P < 0.05). In conclusion, several histopathological changes in liver biopsies could be explained by insulin concentrations, HOMA-IR, and fat mass amount. Moreover, visfatin plasma concentrations could predict the presence of portal inflammation in NAFLD patients.
Dogru T, Sonmez A, Tasci I, et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerant. Diabetes Res Clin Pract. 2006;(Sept):4. (Epub ahead of print).Google Scholar
Li L, Yang G, Li Q, et al. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes. 2006;114:544–548. doi:10.1055/s-2006-948309.PubMedCrossRefGoogle Scholar
El-Assal O, Hong F, Kim WH, Radaeva S, Gao B. IL-6 deficient mice are susceptible to ethanol-induced hepatic steatosis: IL6 protects against ethanol induced stress and mitochondrial permeability. Cell Mol Immunol. 2004;1:205–211.PubMedGoogle Scholar
Retnakaran R, Youn BS, Liu Y, et al. Correlation of circulating full-length visfatin (PBEF/Nampt) with metabolic parameters in subjects with and without diabetes: A cross-sectional study. Clin Endocrinol (Oxf). 2008; Epub ahead of print. oxf.Google Scholar
de Luis DA, Aller R, Izaola O, Conde R, Gonzalez M, Romero E. Effect of a hypocaloric diet on circulating visfatin in obese non diabetic patients. Nutrition. 2008;24:517–521.PubMedCrossRefGoogle Scholar
Pfützner A, Hanefeld M, Lübben G, et al. Visfatin: Aputative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk-results from PIOSTAR study. Horm Metab Res. 2007;39:764–768. doi:10.1055/s-2007-985867.PubMedCrossRefGoogle Scholar